top of page

Fixing the Drug Price Problem [STAT Summit 2026 Review #32]

Nov 10
5 min read

Report 32. Fixing the Drug Price Problem

Part I. English Version


1. Event / Date & Time

Event: Fixing the Drug Price Problem

Conference: STAT Summit 2026

Date & Time: October 15, 2026 | 2:40 PM EDT


2. Participants

Speakers

- Sarah Emond, MPP — President and CEO, Institute for Clinical and Economic Review (ICER)

- Priscilla VanderVeer — Executive Director, No Patient Left Behind


Moderator

- Ed Silverman — Pharmalot Columnist and Senior Writer, STAT


3. Summary

Value and Affordability: The panel explored how drug prices can reflect demonstrated patient benefit while preserving timely access.


Innovation Incentives: The speakers discussed tensions between controlling costs and rewarding risky, expensive pharmaceutical research.


Transparent Debate: Health technology assessment and multi-stakeholder deliberation were proposed as ways to make pricing decisions more credible.


4. Main Discussion

Pricing According to Clinical Evidence

Emond described ICER’s health technology assessment approach, which evaluates what patients gain relative to the price paid. She stressed public methods and participation by patients, clinicians and industry, including people who disagree with the final assessment. Such analysis aims to make constrained healthcare spending decisions more transparent.

Emond explained ICER’s role as an independent organization that evaluates the relationship between evidence of health benefit and the prices paid for care. She emphasized public methods and participation by stakeholders who may disagree with one another. An important source of disagreement was how prescription-drug spending is measured: participants cited figures of about 23% and 14% depending on whether the denominator and categories included particular pharmacy, retail, public and private spending. They did not resolve this into one universal number. The exchange illustrated why debates over affordability can become misleading when different groups compare percentages calculated on different bases. Transparent definitions and evidence standards are therefore necessary before deciding how to balance patient access, innovation incentives and budgets.

Emond introduced the Institute for Clinical and Economic Review as an independent nonprofit that assesses whether healthcare prices are proportionate to the strength of evidence of patient benefit. This approach, often called health technology assessment, asks more than whether a drug produces a statistically detectable signal: it also considers magnitude of benefit, uncertainty and the opportunity cost of spending limited healthcare resources. The organization emphasizes public engagement with patients, clinicians, manufacturers and other parties, including those who disagree with its conclusions. A report’s modeled value is not necessarily the price any individual patient will pay, and methodological judgments remain contestable. The discussion treated transparent deliberation as part of credible pricing analysis.


Rewarding Innovation Without Excluding Patients

VanderVeer argued that society should not treat innovation and affordability as mutually exclusive. She stressed that high-risk drug development needs an incentive system, while patients must be able to obtain successful treatments. The panel explored disagreements over how price negotiation and cost containment may affect future research investment.

VanderVeer argued that innovative medicines are inherently risky and expensive to develop, requiring the prospect of economic returns for investors and developers. At the same time, she maintained that successful products must be affordable enough for patients to use. The panel discussed the difference between rewarding a period of exclusivity and creating lasting barriers after that period; one participant cited price reductions of roughly 80–90% when robust generic competition begins. Those figures were contextual remarks, not a prediction for every therapeutic class. The central policy disagreement concerned the impact of pricing rules and negotiations on the next generation of medicines. The speakers shared an interest in access but differed in how they weighed the risks of reducing development incentives.

VanderVeer approached the same problem from the standpoint of maintaining incentives for difficult and risky innovation. Her organization, No Patient Left Behind, argues that affordability and a strong environment for new drug development need not be mutually exclusive. The central tension is that prices high enough to reward uncertain research may still make treatment inaccessible to patients through coverage restrictions and out-of-pocket costs. The speakers therefore differed in emphasis even when both described patients’ interests as central. The discussion did not settle on a single optimal national pricing formula, and its contrasting viewpoints should be retained rather than merged into artificial agreement.


Evidence, Uncertainty and Coverage

Participants discussed the difficulty of pricing medicines when evidence is incomplete, patient benefit varies or a therapy targets a small population. Health technology assessment was presented as a framework for organizing evidence and trade-offs, not an automatic formula yielding one universally accepted price.

The role of insurers and pharmacy benefit managers became a concrete example of the difference between a negotiated discount and a patient’s out-of-pocket payment. The participants questioned situations in which coinsurance may be calculated using a price that does not reflect the net amount after rebates and negotiations. Both speakers expressed concern that patients may not receive the benefit of large discounts obtained elsewhere in the payment chain. Such arrangements were discussed as targets for nearer-term reform because they directly affect medication adherence and household affordability. The panel did not present a single legislative proposal with proven effects; it emphasized the need to trace where money flows and who ultimately receives the discount.

The discussion considered how evidence evolves after a medicine is approved. Early clinical trials may involve selected populations and limited follow-up, while more complete information about durable benefit, toxicity and use in routine care emerges later. A value assessment could be revised when evidence improves, but uncertainty also creates immediate questions for coverage decisions and negotiations. Speakers discussed the role of patents, exclusivity and the Inflation Reduction Act, including the risk that policy design may affect investment decisions for different drug classes. These statements represented competing policy interpretations; no definitive causal estimate of the law’s long-term innovation impact was presented.


Multi-Stakeholder Pricing Dialogue

The session underscored that pricing discussions affect patients, employers, insurers, government and developers differently. Both transparency and a credible innovation environment were treated as important to sustainable policy, even where speakers disagreed on the appropriate balance.

Evidence uncertainty complicates pricing when products enter the market based on limited follow-up, surrogate endpoints or data from very small populations. ICER’s framework was described as a means of making assumptions and trade-offs visible, not a mechanical equation that generates one uncontested fair price. The panel also discussed government negotiation and the Inflation Reduction Act, including the question of how to handle products whose exclusivity is prolonged without meaningful generic competition. Decisions about pricing can shape manufacturers’ development choices as well as payer coverage and patient access. The session therefore framed fair pricing as a continuing negotiation among clinical value, risk, competition and affordability rather than a problem solved by a single rule.

A practical theme concerned getting better evidence earlier in development. Emond noted that ICER offers scientific advice to companies so developers can consider patient-relevant outcomes and evidence needs before trials are locked in. Such dialogue could reduce the gap between what regulators require for approval and what payers or patients need for value decisions. The session also discussed repurposed therapies and the difficulty of aligning prices with evidence when a medicine’s research and commercialization history differs from that of a newly discovered drug. The point was that pricing policy is inseparable from evidence design, patient participation and the timing of decision-making.


5. Insights

Value-Sensitive R&D: Evidence on patient outcomes and uncertainty can help connect therapeutic innovation with sustainable reimbursement.


Implications for South Korea: Korea could draw on the debate when considering transparent, evidence-based value assessment alongside predictable innovation incentives.


Stakeholder Alignment: Structured dialogue among patients, payers, regulators and manufacturers may reduce conflict around access and drug spending.



Comments


© 2026 KHIDI USA ALL RIGHT RESERVED

bottom of page